Group members

Vandraas KF, Hjorth S, Trewin-Nybråten CB, Ursin G, Botteri E, Andreassen BK, Reinertsen KV, Blix ES, Naume B, Støer NC (2025)
Anti-Her2 therapy patterns in metastatic breast cancer-Real-world data suggest undertreatment
Int J Cancer (in press)
DOI 10.1002/ijc.70120, PubMed 40892038

Bøhn SH, Reinertsen KV, Kiserud CE, Loge JH, Fosså A, Skaali T, Blomhoff R, Oldervoll LM, Courneya KS, Raastad T, Nilsen TS, Wisløff T, Lie HC, Berge T, Edvardsen E, Fagerli UM, Fjerstad E, Gjerset GM, Haavik I, Henriksen HB, Rutkovskiy A, Sandberg G, Seland M, Slott M, Tjessem KH et al. (2025)
Effects of a Multidisciplinary Intervention on Fatigue in Lymphoma Survivors With Chronic Fatigue: Protocol for a Randomized Controlled Trial (REFUEL)
JMIR Res Protoc, 14, e69336
DOI 10.2196/69336, PubMed 40882189

Matikas A, Naume B, Wildiers H, Sonke G, Dieci MV, Karakatsanis A, Andersson A, Barnekow E, Kessler LE, Einbeigi Z, Killander F, Linderholm B, Schiza A, Valachis A, Nearchou A, Engebraaten O, Porojnicu A, Soland MH, Mannsåker B, Raj SX, Blix ES, Nordstrand CS, Lambertini M, Vernieri C, Punie K et al. (2025)
Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE
BMJ Open, 15 (8), e102626
DOI 10.1136/bmjopen-2025-102626, PubMed 40866060